Disease Progression Study for the Treatment of RRMS

Study Title

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS

Teva Identifier

9013

ClinicalTrials.gov Identifier

NCT00202995

Study Status

Terminated

Trial Condition(s)

Relapsing Remitting Multiple Sclerosis

Interventions

Drug: Glatiramer Acetate | Drug: Betaseron | Drug: Rebif

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
ClinicalTrials.gov study records with inclusion and exclusion criteria
neurology icon for clinical trials

Key Participation Requirements

Gender

Female, Male

Age Range

18 Years to 50 Years

Trial Duration

07/01/2004 - 10/01/2007

Phase

Phase 4

Study Type

Interventional